A Dose Escalation, Single Arm, Phase 1b-2 Combination Study of BEZ235 With Everolimus to Determine the Safety, Pharmacodynamics and Pharmacokinetics in Subjects With Advanced Solid Malignancies.
Phase of Trial: Phase I
Latest Information Update: 31 Aug 2017
At a glance
- Drugs Dactolisib (Primary) ; Everolimus (Primary)
- Indications Cancer; Solid tumours
- Focus Adverse reactions
- 29 Mar 2017 Status changed from active, no longer recruiting to completed according to results published in the Targeted Oncology.
- 29 Mar 2017 Results published in the Targeted Oncology
- 17 Jan 2012 New trial record